Key points are not available for this paper at this time.
Artificial intelligence, says futurist Jamie Metzl, is soon to go the way of electricity: impossible to unravel from the fabric of everyday life. The same could be said for AI in drug discovery and development, according to the biotech and pharmaceutical executives and investors who congregated in San Diego for the Biotechnology Innovation Organization (BIO) 2024 International Convention—Metzl among them. The software is increasingly being put toward the work of identifying targets, designing molecules large and small, and trimming down the time it takes to put together a data package for the US Food and Drug Administration. The FDA itself recently launched its first-ever committee dedicated to digital health and AI. "AI won't replace chemists, but chemists that know AI will replace those that don't," Stacie Calad-Thomson, business development lead for Nvidia's health-care and life sciences division, said during a panel discussion on Tuesday. The value of AI isn't new
Rowan Walrath (Mon,) studied this question.